Wednesday, February 10, 08:00 am IST
| Feedback
Moneycontrol » News Center » Business » Business News

Want more about Business to land in your mailbox?

Set an alert here

Ranbaxy launches new drug in the US: PharmAsiaNews

Published on Thu, Nov 26, 2009 at 21:00   |  Updated at Fri, Nov 27, 2009 at 12:16  |  Source : CNBC-TV18

Ranbaxy has launched tablets of blockbuster ant-viral drug Valaciclovir in the US. Analysts expect sales worth USD 200 million in the exclusivity period, reports Vikas Dandekar, of PharmAsiaNews.com

Valaciclovir has been branded as Valtrex by GlaxoSmithKline Pharmaceuticals. It has annual sales of over USD 2 billion in the US. Ranbaxy has a 'First To File' status for Valaciclovir. When contacted, Ranbaxy confirmed the launch.

In an interview to CNBC-TV18, Dandekar, the India Bureau Chief of PharmAsiaNews.com gave exclusive details about the new drug's launch and the opportunity it presents for Ranbaxy.


RSS feed for news
Click here

Here is a verbatim transcript of the exclusive interview with Vikas Dandekar on CNBC-TV18. Also watch the accompanying video.

Q: Take us through the drug details and also what sort of an opportunity this really is for Ranbaxy?

A: This is one of the most awaited drug launches for Ranbaxy, especially in the wake of all the regulatory issues that it has been facing from the FDA. It is a definite and big upside so far as Ranbaxy is concerned. The launch of Valaciclovir generic, it is part of an out-of- court settlement that Ranbaxy did and the patent expiry happens sometimes next month.

The size of the product is quite large, USD 2.2 billion in the US. At a very conservative estimate, analysts have been saying that it will be in the range of USD 175 million to USD 200 million, plus exclusivity period that Ranbaxy will be getting.

So on November 25, the company finally launched 500 mg and 1 gm tablets of Valaciclovir. It is seen as a definite positive for the company. The big thing is there is no authorised generic as yet. So, it will be a clean play for Ranbaxy for six months, as of now, making it a definite positive for the company.

CEO Wall See All

Harsh Manglik

Harsh Manglik

Chairman

Accenture India

Accenture India to hire aggressively for select verticals

Vishal Doshi

Vishal Doshi

Managing Director

Shrenju & Company

Shrenuj & Company will project 15% rev rise this yr

MP Taparia

MP Taparia

Chairman

Supreme Petrochemicals

Supreme Petrochemicals expects Rs 2200cr rev in next 1.5yrs

Vineet Nayyar

Vineet Nayyar

Chief Executive Officer

HCL Technologies

HCL Tech plans to merge arms with itself, eyes new spots

WHAT OTHERS LIKE
  • Most Read
  • Most Viewed
24 Hours
7 Days
1 Month
NEWS FROM OUR PARTNERS
©Network 18, 2010. All Rights Reserved